Nalini Ghag-Motwani, Ph.D.

President & Founding Chief Scientist

Dr. Motwani has over 25 years of experience in research and management in the field  of biotechnology including recombinant protein production.

Dr. Motwani is a co-inventor of five issued patents on yeast expression system for  the production of recombinant proteins. Prior to founding BioSavita, Dr. Motwani was one of the founding  scientists of Strohtech/Apex Bioscience, which was involved in the development of a cost-effective yeast expression system to produce genetically engineered hemoglobin.   Dr. Motwani has been successful in securing NIH-SBIR and state grants, private funds, and licenses with biopharma for BioSavita.  She was a licensing consultant for the technology transfer office at the University of Michigan and a visiting scientist at the Karolinska Institute in Sweden.   She received her Master’s degree from Haffkine Institute in Bombay and her Ph.D. from Wayne State University in Michigan.

Jerry Choate, BA

Chief Financial Officer

Mr. Choate has more than 20 years of experience in corporate finance as a business founder, investment banker, business development director, and strategic advisor for various public and private healthcare, life sciences, biotechnology, and pharmaceutical companies. He also serves as founder and Managing Partner of Think Capital Advisors, a privately held specialty, global advisory firm that combines growth strategy, corporate finance for life sciences, healthcare, and technology sectors to drive shareholder value.

During his tenure, Think Capital Advisors successfully assisted early stage companies to profitability and participated in over $1 billion of corporate finance advisory. Mr. Choate has also served as Managing Director at  MidSouth Capital, a boutique investment banking group. One of his clients at MidSouth was eventually sold to GE Healthcare for $587 million. Mr. Choate has further served as Managing Director at Moody Capital, a boutique investment banking group focusing on venture financing and public financing in the life sciences and healthcare market.  He graduated from the University of South Carolina’s Business School and completed a global business program at the Economics University of Vienna, Austria.

Savita Nikam, Ph.D.

Director of Research

Dr. Nikam has more than 20 years of research experience in academia and with biotechnology companies. Her expertise includes molecular biology, protein biochemistry and expression of products from mammalian, yeast and bacterial expression systems. Dr. Nikam gained extensive experience at Molecular Imaging Research (Charles River Company) in manipulating different cancer cell lines and generating reporter models for in vivo imaging of apoptosis following new cancer drug treatment. Her Ph.D. research included development of a potent viral vaccine against  Japanese Encephalitis from primary chick embryo cell cultures. Dr. Nikam received her Ph.D. in Microbiology from National Institute of Virology, Pune University, India. She completed her postdoctoral research on mechanism of HIV reverse transcriptase fidelity and the kinetic basis of drug resistance at the University of Michigan.

i thought about this